**Name of Journal:** *World Journal of Clinical Infectious Diseases*

**Manuscript NO:** 57238

**Manuscript Type:** LETTER TO THE EDITOR

**COVID-19 and dengue coinfection in Brazil**

Figueredo MS *et al.* COVID-19 and dengue coinfection

Millena Santos Figueredo, Taise de Alcântara Amâncio, Jaime Arandia Salvatierra, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Dulciene Maria de Magalhães Queiroz, Fabrício Freire de Melo

**Millena Santos Figueredo, Taise de Alcântara Amâncio, Jaime Arandia Salvatierra,** City Hall of Vitória da Conquista, City Hall of Vitória da Conquista, Vitória da Conquista 45000-907, Bahia, Brazil

**Breno Bittencourt de Brito, Filipe Antônio França da Silva, Fabrício Freire de Melo,** Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil

**Dulciene Maria de Magalhães Queiroz,** Laboratory of Research in Bacteriology, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte 30130-100, Minas Gerais, Brazil

**Author contributions:** Figueredo MS, Amâncio TA, Salvatierra JA, de Brito BB, da Silva FAF, Queiroz DMM, and de Melo FF equally contributed to this work.

**Corresponding author: Fabrício Freire de Melo, PhD, Postdoc, Professor,** Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros, 58, Quadra 17, Lote 58, Vitória da Conquista 45029-094, Bahia, Brazil. [freiremelo@yahoo.com.br](mailto:freiremelo@yahoo.com.br)

**Received:** May 29, 2020

**Revised:** September 5, 2020

**Accepted:** September 14, 2020

**Published online:**

**Abstract**

The case we present here is a man who lives in a dengue-endemic area. Initially, the patient was diagnosed with dengue fever by clinical evaluation and laboratorial confirmation. Subsequently, he presented respiratory symptoms, and a concomitant severe acute respiratory syndrome coronavirus 2 infection was confirmed. He was hospitalized for 17 d and had a satisfactory recovery.

**Key Words:** COVID-19; Dengue fever; SARS-CoV-2; Dengue virus; Coinfection; Diagnosis

Figueredo MS, Amâncio TA, Salvatierra JA, de Brito BB, da Silva FAF, Queiroz DMM, de Melo FF. COVID-19 and dengue coinfection in Brazil. *World J Clin Infect Dis* 2020; In press

**Core Tip:** Corona virus disease 2019 represents a big concern for public health. Simultaneously, many countries are also being affected by arbovirus epidemics, which overwhelms the health assistance services from those localities. That scenario calls attention to how these epidemics will affect the health of people living in those geographic areas. In this Letter to the Editor, we report a coinfection by severe acute respiratory syndrome coronavirus 2 and dengue virus that occurred in northeastern Brazil.

**TO THE EDITOR**

From the first cases reported in December 2019 in Wuhan, China, to May 13, 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected 4179479 people worldwide[1,2]. Concomitant to the corona virus disease 2019 (COVID-19) pandemic, half of the world population is at increased risk of developing arbovirus infections, and 390 million individuals are infected by the dengue virus (DENV) every year, which makes the world health scenario even more worrying[3]. Here we report a coinfection by SARS-CoV-2 and DENV that occurred in a patient from northeastern Brazil.

This study was approved by the National Commission of Research Ethics, from the National Health Council, Ministry of Health of Brazil (Number 30700320.0.0000.0008), and a signed informed consent was obtained from the patient.

The case is a 59-year-old physician male with well-controlled comorbidities (hypertension and type 2 diabetes, in use of an angiotensin converting enzyme inhibitor and metformin) living in a dengue-endemic area with no history of recent travel. He requested medical home care on March 30, 2020 due to the onset of symptoms such as fever, chills, anorexia, and headache. Three days later, the patient was tested by immunochromatography assay for specific dengue immunoglobulins (94% sensitivity and 96% specificity). Positive IgM and negative IgG results along with the clinical data led to the diagnosis of dengue fever.

On the fourth day, the patient presented dyspnea and cough, and a bilateral ground-glass pattern was observed in his lungs by a thoracic computerized tomography. He was immediately hospitalized and found to be positive for SARS-CoV-2 infection by serology (positive IgM and IgG immunoglobulins) and by RT-PCR of the material obtained by a nasopharyngeal swab. The liver and kidney tests were within the reference values as well as the blood counts.

Two days later, the patient presented a hypoxemic respiratory insufficiency and was transferred to an intensive care unit. He underwent noninvasive oxygen therapy and developed a deep vein thrombosis in the right femoral vein, which was accompanied by increased D-dimer values. He received full-dose heparin therapy followed by full-dose enoxaparin prophylaxis. The patient was kept in the intensive care unit for 12 d and was subsequently transferred to conventional hospital care.

Five days later, a COVID-19 serological test was negative for IgM and positive for IgG, and he was discharged from the hospital with a rivaroxaban (30 mg/d) prescription. Three weeks after hospital discharge, he underwent a new immunochromatography assay for dengue diagnosis (94% sensitivity and 96% specificity), and IgG dengue specific immunoglobulin was positive, representing a seroconversion and confirming the concomitant diagnosis of dengue fever and COVID-19.

It has to be emphasized that there was an increase of about 70% in the number of dengue cases in Brazil in the period from December 30, 2019 to March 12, 2020 (390684 cases reported) compared to the same period in 2018-2019 (229064 cases reported)[4,5]. In addition, according to the Pan American Health Organization, Brazil registered 2226865 dengue cases in 2019, 70% of the total in the Americas[6]. Not only Brazil, but also all of the dengue-endemic world regions are at risk of suffering the consequences of the threatening cocirculation of those viruses[7,8]. As an example, a prior publication called attention to Colombia, which registered 52679 dengue notifications and 14943 COVID-19 cases during the first five months of 2020[9]. Interestingly, a study demonstrated a considerable drop in the number of dengue cases notified during the COVID-19 epidemic in the State of São Paulo, Brazil[10]. This study hypothesized that there might be an under notification of dengue cases due to the impairments in health system functioning because of the COVID-19 epidemic. The authors also theorized that the restriction of the social interactions aiming to limit the SARS-CoV-2 dissemination resulted in a lower circulation of people and could have reduced the propagation of arboviruses, decreasing the risk of dengue outbreaks in various geographic areas.

The case reported here joins some previously published descriptions of dengue and COVID-19 coinfections. The first reported DENV and SARS-CoV-2 coinfection dates from March 11, 2020 and affected a 44-year-old male living at Mayotte in the Indian Ocean, who traveled to Switzerland and France, where his symptoms started[11]. Verduyn *et al*[12] reported another coinfection in an 18-year-old male who traveled from France to Reunion Island, also located in the Indian ocean. We have just also published a similar coinfection in a Brazilian man aged 39 years, who lived in a small county with no prior register of COVID-19 circulation and had the onset of symptoms three days after a day trip to another city[13]. Interestingly, all of the above mentioned case reports refer to travelers who potentially acquired each of the infections in different geographic areas.

In contrast, the present report describes a coinfection in a patient who had not traveled before falling ill. Such data alerts to the occurrence of a local circulation of both viruses, which can lead to serious impacts in the regional public health. Moreover, all of the previously reported cases are young adults who did not experience severe respiratory symptoms unlike the patient reported here, who also had type 2 diabetes and hypertension, two well-known risk factors for unfavorable COVID-19 outcomes.

Although the patient underwent intensive medical care and supplementary oxygen, he had a satisfactory recovery with no necessity for intubation. Some authors believe that metformin may play a protective role in diabetic COVID-19 patients because this medication has promising results when used in other lung diseases such as asthma and pneumonia[14]. Moreover, a retrospective cohort study analyzing 223 diabetic individuals who had dengue fever found a lower risk of developing severe dengue among metformin users[15]. In addition, we hypothesize that the interplay between those infections may influence the immune response in an idiosyncratic way. However, deeper analysis on that issue could not be performed in the present case, and further studies should be conducted in order to better understand such a relationship.

The existence of clinical similarities between COVID-19 and dengue fever can lead to misdiagnoses, which may delay important clinical measures for the management of patients. Waterman *et al*[16] drew attention to the need for physicians in dengue-endemic areas to be alert for recognizing clinical characteristics associated with severe dengue fever in individuals with a suspected SARS-CoV-2 infection. On the other hand, the report of a 35-year-old nurse who likely got COVID-19 while sampling blood of a man who was presumed to have dengue fever highlights the risks of covert SARS-CoV-2 infections in dual viral circulation settings[17]. Complementarily, the occurrence of false-positive serology for dengue in SARS-CoV-2-infected individuals in Singapore reinforce the necessity of careful management of patients with nonspecific clinical presentations in coepidemic scenarios[18]. The discussion above gains even more importance when considering that laboratory parameters such as thrombocytopenia can be observed in both infections[19]. Taken together, health systems of dengue-endemic regions should consider social isolation procedures for patients without a clear etiologic diagnosis aiming to avoid the SARS-CoV-2 dissemination.

In view of the potential risks of a coinfection by SARS-CoV-2 and DENV, we highlight the importance of this Letter to the Editor as a way to alert health professionals to consider both diagnoses in countries simultaneously affected by these epidemics.

**REFERENCES**

1 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

2 **World Health Organization.** WHO Coronavirus Disease (COVID-19) Dashboard. [cited 13 May 2020] In: World Health Organization [Internet] Available from: <https://covid19.who.int/>

3 **World Health Organization.** Dengue and severe dengue. [cited 13 May 2020] In: World Health Organization [Internet] Available from: <https://www.who.int/en/news-room/fact-sheets/detail/dengue-and-severe-dengue>

4 **Ministério da Saúde do Brasil.** Monitoramento dos casos de arboviroses urbanas transmitidas pelo Aedes (dengue, chikungunya e Zika) até a Semana Epidemiológica 11 de 2019. [cited 14 May 2020] In: Ministério da Saúde do Brasil [Internet]. Available from: <https://www.saude.gov.br/images/pdf/2019/marco/25/2019-013-Monitoramento-dos-casos-de-arboviroses-publicacao-25-03-2019.pdf>

5 **Ministério da Saúde do Brasil.** Monitoramento dos casos de arboviroses urbanas transmitidas pelo Aedes Aegypti (dengue, chikungunya e zika), Semanas Epidemiológicas 1 a 11, 2020. [cited 14 May 2020] In: Ministério da Saúde do Brasil [Internet]. Available from: <https://www.saude.gov.br/images/pdf/2020/marco/30/Boletim-epidemiologico-SVS-12.pdf>

6 **Pan American Health Organization.** Epidemiological Update Dengue. [cited 14 May 2020] In: Pan American Health Organization [Internet]. Available from: <https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=dengue-2217&alias=51690-7-february-2020-dengue-epidemiological-update-1&Itemid=270&lang=en>

7 **Miah MA**, Husna A. Coinfection, coepidemics of COVID-19, and dengue in dengue-endemic countries: A serious health concern. *J Med Virol* 2020 [PMID: 32633829 DOI: 10.1002/jmv.26269]

8 **Din M**, Asghar M, Ali M. COVID-19 and dengue coepidemics: A double trouble for overburdened health systems in developing countries. *J Med Virol* 2020; : [PMID: 32706408 DOI: 10.1002/jmv.26348]

9 **Cardona-Ospina JA**, Arteaga-Livias K, Villamil-Gómez WE, Pérez-Díaz CE, Katterine Bonilla-Aldana D, Mondragon-Cardona Á, Solarte-Portilla M, Martinez E, Millan-Oñate J, López-Medina E, López P, Navarro JC, Perez-Garcia L, Mogollon-Rodriguez E, Rodríguez-Morales AJ, Paniz-Mondolfi A. Dengue and COVID-19, overlapping epidemics? An analysis from Colombia. *J Med Virol* 2020 [PMID: 32558962 DOI: 10.1002/jmv.26194]

10 **Lorenz C**, Dias Bocewicz AC, Corrêa de Azevedo Marques C, Reis Santana LM, Chiaravalloti-Neto F, Alves Gomes AH, Barbosa GL. Have measures against COVID-19 helped to reduce dengue cases in Brazil? *Travel Med Infect Dis* 2020; **37**: 101827 [PMID: 32745594 DOI: 10.1016/j.tmaid.2020.101827]

11 **Epelboin L**, Blondé R, Nacher M, Combe P, Collet L. COVID-19 and dengue co-infection in a returning traveller. *J Travel Med* 2020 [PMID: 32657339 DOI: 10.1093/jtm/taaa114]

12 **Verduyn M**, Allou N, Gazaille V, Andre M, Desroche T, Jaffar MC, Traversier N, Levin C, Lagrange-Xelot M, Moiton MP, Hoang S. Co-infection of dengue and COVID-19: A case report. *PLoS Negl Trop Dis* 2020; **14**: e0008476 [PMID: 32745101 DOI: 10.1371/journal.pntd.0008476]

13 **Pontes RL**, de Brito BB, da Silva FAF, Figueredo MS, Correia TML, Teixeira AF, Oliveira MV, de Melo FF. Coinfection by SARS-CoV-2 and dengue virus in a dual viral circulation setting. *Travel Med Infect Dis* 2020; **37**: 101862 [PMID: 32858249 DOI: 10.1016/j.tmaid.2020.101862]

14 **El-Arabey AA**, Abdalla M. Metformin and COVID-19: A novel deal of an old drug. *J Med Virol* 2020; Online ahead of print [PMID: 32347974 DOI: 10.1002/jmv.25958]

15 **Htun HL**, Yeo TW, Tam CC, Pang J, Leo YS, Lye DC. Metformin Use and Severe Dengue in Diabetic Adults. *Sci Rep* 2018; **8**: 3344 [PMID: 29463812 DOI: 10.1038/s41598-018-21612-6]

16 **Waterman SH**, Paz-Bailey G, San Martin JL, Gutierrez G, Castellanos LG, Mendez-Rico JA. Diagnostic Laboratory Testing and Clinical Preparedness for Dengue Outbreaks during the COVID-19 Pandemic. *Am J Trop Med Hyg* 2020; **103**: 1339-1340 [PMID: 32723428 DOI: 10.4269/ajtmh.20-0884]

17 **Prasitsirikul W**, Pongpirul K, Pongpirul WA, Panitantum N, Ratnarathon AC, Hemachudha T. Nurse infected with Covid-19 from a provisional dengue patient. *Emerg Microbes Infect* 2020; **9**: 1354-1355 [PMID: 32458742 DOI: 10.1080/22221751.2020.1775131]

18 **Yan G**, Lee CK, Lam LTM, Yan B, Chua YX, Lim AYN, Phang KF, Kew GS, Teng H, Ngai CH, Lin L, Foo RM, Pada S, Ng LC, Tambyah PA. Covert COVID-19 and false-positive dengue serology in Singapore. *Lancet Infect Dis* 2020; **20**: 536 [PMID: 32145189 DOI: 10.1016/S1473-3099(20)30158-4]

19 **Bansal N**, Bansal Y, Ralta A. Thrombocytopenia in COVID-19 patients in Himachal Pradesh (India) and the absence of dengue false-positive tests: Insights for patient management. *J Med Virol* 2020 [PMID: 32729946 DOI: 10.1002/jmv.26373]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the authors who contributed their efforts in this manuscript

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 29, 2020

**First decision:** August 23, 2020

**Article in press:**

**Specialty type:** Infectious diseases

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** El-Arabey A, Tárnok A, Torti C **S-Editor:** Zhang L **L-Editor:** Filipodia **P-Editor:**